Trials / Completed
CompletedNCT01999699
A Study of the Immune Response to Heplisav in Healthy Older Adults
A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Dynavax Technologies Corporation · Industry
- Sex
- All
- Age
- 50 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.
Detailed description
The purpose of this study is to examine how the immune system responds to vaccination with HEPLISAV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HEPLISAV |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-02-01
- Completion
- 2015-03-01
- First posted
- 2013-12-03
- Last updated
- 2019-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01999699. Inclusion in this directory is not an endorsement.